• CUPR is trading at $6.16 (6.5% down) in after-hours as investors lock in gains following a sharp rally. The stock surged over 47% on June 30 after Cuprina announced FDA 510(k) clearance for its Medifly Maggots wound-care therapy.
  • This significant rally, which saw intraday gains exceeding 100%, followed an earlier surge in mid-June when the company regained Nasdaq listing compliance.
  • Today's decline appears to be profit-taking after the recent spike, amidst broader modest weakness in crypto markets.